PL1732898T3 - Pochodne tetrahydroizochinoliny i tetrahydrobenzazepiny jako inhibitory IGF-1R - Google Patents

Pochodne tetrahydroizochinoliny i tetrahydrobenzazepiny jako inhibitory IGF-1R

Info

Publication number
PL1732898T3
PL1732898T3 PL04719900T PL04719900T PL1732898T3 PL 1732898 T3 PL1732898 T3 PL 1732898T3 PL 04719900 T PL04719900 T PL 04719900T PL 04719900 T PL04719900 T PL 04719900T PL 1732898 T3 PL1732898 T3 PL 1732898T3
Authority
PL
Poland
Prior art keywords
tetrahydroisoquinoline
igf
inhibitors
tetrahydrobenzazepine derivatives
tetrahydrobenzazepine
Prior art date
Application number
PL04719900T
Other languages
English (en)
Inventor
Jan Gunzinger
Kurt Leander
Original Assignee
Analytecon Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Analytecon Sa filed Critical Analytecon Sa
Publication of PL1732898T3 publication Critical patent/PL1732898T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04719900T 2004-03-12 2004-03-12 Pochodne tetrahydroizochinoliny i tetrahydrobenzazepiny jako inhibitory IGF-1R PL1732898T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04719900A EP1732898B1 (en) 2004-03-12 2004-03-12 Tetrahydroisoquinoline- and tetrahydrobenzazepine derivatives as igf-1r inhibitors
PCT/CH2004/000147 WO2005087743A1 (en) 2004-03-12 2004-03-12 Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors

Publications (1)

Publication Number Publication Date
PL1732898T3 true PL1732898T3 (pl) 2008-06-30

Family

ID=34957074

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04719900T PL1732898T3 (pl) 2004-03-12 2004-03-12 Pochodne tetrahydroizochinoliny i tetrahydrobenzazepiny jako inhibitory IGF-1R

Country Status (21)

Country Link
US (1) US7875631B2 (pl)
EP (1) EP1732898B1 (pl)
JP (1) JP2007528877A (pl)
CN (1) CN100590118C (pl)
AR (1) AR049323A1 (pl)
AT (1) ATE384700T1 (pl)
AU (1) AU2004317166B2 (pl)
BR (1) BRPI0418462A (pl)
CA (1) CA2555745C (pl)
DE (1) DE602004011578T2 (pl)
DK (1) DK1732898T3 (pl)
EA (1) EA200601687A1 (pl)
ES (1) ES2299825T3 (pl)
IL (1) IL177307A (pl)
NO (1) NO20063794L (pl)
PL (1) PL1732898T3 (pl)
PT (1) PT1732898E (pl)
SI (1) SI1732898T1 (pl)
TW (1) TW200530213A (pl)
WO (1) WO2005087743A1 (pl)
ZA (1) ZA200607198B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200800786A1 (ru) * 2005-09-09 2008-08-29 Аналитикон С.А. Тетрагидроизохинолиновые и тетрагидробензоазепиновые производные в качестве igf-1r ингибиторов, способ лечения или профилактики заболеваний, при которых благоприятна деактивация igf-1r, изделие для введения производных и хемотерапевтических агентов в комбинации, фармакологический инструмент для разработки и стандартизации тест-систем
NZ566524A (en) * 2005-09-09 2011-01-28 Analytecon Sa Isoquinolines as IGF-1R inhibitors
WO2009073203A1 (en) 2007-12-04 2009-06-11 Amgen Inc. Trp-m8 receptor ligands and their use in treatments
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
BR112013000254A2 (pt) * 2010-07-05 2016-05-24 Actelion Pharmaceuticals Ltd derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
MX2013008833A (es) 2011-02-02 2013-12-06 Amgen Inc Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
AU2012335541B2 (en) 2011-11-11 2017-07-06 Duke University Combination drug therapy for the treatment of solid tumors
CN104011021B (zh) 2011-12-21 2016-08-24 埃科特莱茵药品有限公司 杂环衍生物及其作为前列腺素d2受体调节剂的用途
WO2014006585A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
CN104672136B (zh) * 2013-11-30 2017-01-25 沈阳药科大学 1‑取代菲基‑n‑烷基(酰基)‑6,7‑二甲氧基‑1,2,3,4‑四氢异喹啉衍生物及其制备方法和用途
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
CN112500345B (zh) * 2020-12-18 2022-06-21 西安石油大学 α-氰基季碳取代四氢异喹啉化合物的合成方法
WO2024067463A1 (zh) * 2022-09-27 2024-04-04 苏州阿尔脉生物科技有限公司 苯并[7]环烯类衍生物、包含其的药物组合物及其医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349472A (en) 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
CA1330560C (en) * 1986-05-21 1994-07-05 Maurits E. A. Vandewalle Di- and tetrahydroisoquinoline derivatives
WO1990002119A1 (en) * 1988-08-18 1990-03-08 Banyu Pharmaceutical Co., Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
US6337338B1 (en) * 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
EP1341765A1 (en) * 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic compounds
SE0102168D0 (sv) 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
GB0212303D0 (en) 2002-05-28 2002-07-10 Isis Innovation Molecular targetting of IGF-1 receptor

Also Published As

Publication number Publication date
SI1732898T1 (sl) 2008-06-30
ES2299825T3 (es) 2008-06-01
WO2005087743A1 (en) 2005-09-22
US7875631B2 (en) 2011-01-25
AU2004317166A1 (en) 2005-09-22
EP1732898A1 (en) 2006-12-20
AU2004317166B2 (en) 2010-11-11
DK1732898T3 (da) 2008-05-13
ATE384700T1 (de) 2008-02-15
PT1732898E (pt) 2008-04-07
TW200530213A (en) 2005-09-16
US20070129399A1 (en) 2007-06-07
IL177307A0 (en) 2006-12-10
NO20063794L (no) 2006-12-12
DE602004011578D1 (de) 2008-03-13
EA200601687A1 (ru) 2007-04-27
CA2555745A1 (en) 2005-09-22
CN100590118C (zh) 2010-02-17
IL177307A (en) 2011-09-27
AR049323A1 (es) 2006-07-19
ZA200607198B (en) 2008-04-30
CN1922147A (zh) 2007-02-28
EP1732898B1 (en) 2008-01-23
CA2555745C (en) 2011-05-31
BRPI0418462A (pt) 2007-06-05
JP2007528877A (ja) 2007-10-18
DE602004011578T2 (de) 2009-02-19

Similar Documents

Publication Publication Date Title
IL177307A0 (en) Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
ZA200610771B (en) Quinazolinedolone derivatives as PARP inhibitors
TWI370127B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
PL1763517T3 (pl) Pochodne pirymidyny jako inhibitory 11BETA-HSD1
IL177278A0 (en) Pyrazolotriazines as kinase inhibitors
IL179398A0 (en) Dpp-ib inhibitors
IL185185A0 (en) Azolylacylguanidines as ??-secretase inhibitors
EP1847532A4 (en) IGF-1R Inhibitor
ZA200806148B (en) 2-adamantylurea derivatives as selective 11ß-HSD1 inhibitors
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
IL179305A0 (en) Dpp-iv inhibitors
EP1778693A4 (en) AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
IL183140A0 (en) Substituted benzoquinolizine derivatives
IL189112A0 (en) NOVEL HETEROCYCLIC NF-kB INHIBITORS
EP1968581A4 (en) TETRACYCLIC KINASE INHIBITORS
HK1100002A1 (en) 4-phenyl-pyrimidine-2-carbonitrile derivatives
IL182739A0 (en) Acylatednonadepsipeptides used as lysobactin derivatives
SI1740574T1 (sl) Derivati 4-amino-5-cianopirimidina
IL174845A0 (en) Benzazepine derivatives as mao-b inhibitors
GB0421355D0 (en) Inhibitors
ZA200702325B (en) 2-acylaminothiazole derivatives
GB0421356D0 (en) Inhibitors
ZA200706212B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors